News | July 02, 2025
Cadila Pharmaceuticals launches Bilacad Dex Syrup
A triple-action Formula for comprehensive respiratory relief
A triple-action Formula for comprehensive respiratory relief
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Changhua site meets international regulatory standards for global medical applications
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
